Adamantyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 19, 2005, Pages 4359-4362

  Olson, Steven ^a   Aster, Susan D ^a   Brown, Kai ^a   Carbin, Linda ^a   Graham, Donald W ^a   Hermanowski Vosatka, Anne ^a   LeGrand, Cheryl B ^a   Mundt, Steven S ^a   Robbins, Michael A ^a   Schaeffer, James M ^a   Slossberg, Llnon H ^a   Szymonifka, Michael J ^a   Thieringer, Rolf ^a   Wright, Samuel D ^a   Balkovec, James M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

11 HSD1; Adamantyl triazole; Metabolic syndrome

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE 1; ADAMANTANE DERIVATIVE; OXIDOREDUCTASE INHIBITOR; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADAMANTANE; ANIMALS; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; METABOLIC SYNDROME X; MICE; PHARMACOKINETICS; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 23944454884     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.06.040     Document Type: Article

References (34)

1. For recent reviews see: J.W. Tomlinson, E.A. Walker, I.J. Bujalska, N. Draper, G.G. Lavery, M.S. Cooper, M. Hewison, and P.M. Stewart Endocr. Rev. 25 2004 831
2. J.R. Seckl, and B.R. Walker Trends Endocrinol. Metab. 15 2004 418
3. E.A. Walker, and P.M. Stewart Trends Endocrinol. Metab. 14 2003 334
4. B.R. Walker, and J.R. Seckl Expert Opin. Ther. Targets 7 2003 771
5. Metabolism 15 2004 418
6. M.B. Feinstein, and R.P. Schleimer N.J. Goulding P.J. Flower Glucocorticoids 2001 Birkhëuser Switzerland 147 158
7. For recent reviews see: T.M. Stulnig, and W. Waldhäusl Diabetologia 47 2004 1
8. M. Quinkler, W. Oelkers, and S. Diederich Eur. J. Endocrinol. 144 2001 87
9. M. Wang Nutr. Metab. 2:3 2005 1
10. J.W. Tomlinson, and P.M. Stewart Horm. Metab. Res. 34 2002 746
11. For a review see: P.C. White, T. Mune, and A.K. Agarwal Endocr. Rev. 18 1997 135
12. Y.V. Kotelevtsev, R.W. Brown, S. Fleming, C.R. Edwards, J.R. Seckl, and J.J. Mullins J. Clin. Invest. 103 1999 683
13. R.C. Wilson, M.D. Harbision, Z.S. Krozowski, J.W. Funder, C.H. Shackleton, H.M. Hanauske-Abel, J.Q. Wei, J. Hertecant, A. Moran, and R.E. Neiberger Clin. Endocrinol. Metab. 80 1995 3145
14. C. Monder, P.M. Stewart, V. Lakshmi, R. Valentino, D. Burt, and C.R. Edwards Endocrinology 125 1989 1046
15. C.B. Whorwood, M.C. Sheppard, and P.M. Stewart Endocrinology 132 1993 2287
16. A.L. Albiston, V.R. Obeyesekere, R.E. Smith, and Z.S. Krozowski Mol. Cell. Endrocrinol. 105 1994 R11
17. P.M. Stewart, A.M. Wallace, R. Valentino, D. Burt, C.H.L. Shackleton, and C.R.W. Edwards Lancet 330 1987 821
18. P.M. Stewart, A.M. Wallace, S.M. Atherden, C. Shearing, and C.R.W. Edwards Clin. Sci. 78 1990 49
19. R.C. Andrews, O. Rooyackers, and B.R. Walker J. Clin. Endocrinol. Metab. 88 2003 285
20. T.C. Sandep, J.L.W. Yau, A.M.J. MacLullich, J. Noble, I.J. Deary, B.R. Walker, and J.R. Seckl Proc. Natl. Acad. Sci. U.S.A. 101 2004 6734
21. T. Barf, J. Vallgårda, R. Emond, C. Häggström, G. Kurz, A. Nygren, V. Larwood, E. Mosialou, K. Axelsson, R. Olsson, L. Engblom, N. Edling, Y. Rönquist-Nii, B. Öhman, P. Alberts, and L. Abrahmsén J. Med. Chem. 45 2002 3813
22. C. Fotsch, B.C. Askew, and J.J. Chen Expert Opin. Ther. Patents 15 2005 289
23. R.A.S. Schweizer, A.G. Atanasov, B.M. Frey, and A. Odermatt Mol. Cell. Endocrinol. 212 2003 41
24. S. Diederich, C. Grossmann, B. Hanke, M. Quinkler, M. Herrmann, V. Bahr, and W. Oelkers Eur. J. Endocrinol. 142 2000 200
25. M.A. Koch, L.-O. Wittenberg, S. Basu, D.A. Jeyaraj, E. Gourzoulidou, K. Reinecke, A. Odermatt, and H. Waldmann Proc. Natl. Acad. Sci. U.S.A. 101 2004 16721
26. J. Xiang, M. Ipek, V. Suri, W. Massefski, N. Pan, Y. Ge, M. Tam, Y. Xing, J.F. Tobin, and S. Tam Bioorg. Med. Chem. Lett. 15 2005 2865
27. The in vitro enzymatic activity was assessed via a scintillation proximity assay (SPA). Tritiated-cortisone, NADPH, and test compound were incubated with 11β-HSD1 from CHO transfectants at 37°C to allow conversion to cortisol to progress. Following incubation, a preparation of protein A-coated SPA beads, pre-blended with anti-cortisol monoclonal antibody MAb and a nonspecific 11β-HSD1 inhibitor (18β-glycyrrhetinic acid), was added to each well. The mixture was read on a scintillation counter. This is similar to the method described in Ref. 8a.
28. Hermanowski-Vosatka, A.; Balkovec, J. M.; Cheng, K.; Chen, H. Y.; Hernandez, M.; Koo, G. C.; Le Grand, C. B.; Li, Z.; Metzger, J. M.; Mundt, S. S.; Noonan, H.; Nunes, C. N.; Olson, S. H.; Pikounis, B.; Ren, N.; Robertson, N.; Schaeffer, J. M.; Shah, K.; Springer, M. S.; Strack, A. M.; Strowskil, M.; Wu, K.; Wu, T.; Xiao, J.; Zhang, B. B.; Wright, S. D.; Thieringer, R. J. Exp Med. in press.
29. S. Petersen, and E. Tietze Chem. Ber. 90 1957 909
30. Noncommercial hydrazides were best prepared on small scale from the corresponding acid following the procedure of U. Boas, B. Pedersen, and J.B. Christensen Synth. Commun. 28 1998 1223 On large scale, the methyl ester was heated with excess hydrazine to provide the hydrazide in good yield
31. J.R. Alford, B.D. Cuddy, D. Grant, and M.A. McKervey J. Chem. Soc., Perkin Trans. 1 1972 2707
32. Prepared by the reaction of 14 with (diethylamino)sulfur trifluoride (DAST) in dichloromethane at room temperature.
33. (3,5-Dimethyl-1-adamantyl)acetic acid was prepared by the method of K. Bott Chem. Ber. 101 1968 564
34. D.B. Reitz, and M.J. Finkes J. Heterocycl. Chem. 26 1989 225